Lyumjev FDA Approval History
FDA Approved: Yes (First approved June 15, 2020)
Brand name: Lyumjev
Generic name: insulin lispro-aabc
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Diabetes, Type 1, Diabetes, Type 2
Lyumjev (insulin lispro-aabc) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.
- Lyumjev (insulin lispro-aabc) is a novel formulation of insulin lispro, which is marketed as Humalog.
- Lyumjev 100 units/mL (U-100) injection is available as multiple-dose vials, and single-patient-use prefilled pens and cartridges. Lyumjev 200 units/mL (U-200) injection is available as multiple-dose vials.
- Lyumjev is administered subcutaneously into the abdomen, upper arm, thigh, or buttocks at the start of a meal, or within 20 minutes after starting a meal. Lyumjev (U-100) is administered intravenously only under medical supervision.
- Side effects include hypoglycemia, injection site reactions, allergic reactions, rash, pruritus, lipodystrophy, and weight gain.
Development Timeline for Lyumjev
|Jun 15, 2020||Approval FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.